Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  Sumitomo Dainippon Pharma Co Ltd    4506   JP3495000006

SUMITOMO DAINIPPON PHARMA CO LTD

(4506)
  Report  
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations
The feature you requested does not exist. However, we suggest the following feature:

Sumitomo Dainippon Pharma : to Open a New Office for its Regenerative Medicine/Cell Therapy Business in San Diego, U.S

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/09/2019 | 08:06am EDT

Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura) announced today that it will open a new office in San Diego, California, in June 2019.

The new office will be responsible for advancing product development, building a network, exploring new research seeds, and gathering technological information for the Regenerative Medicine/Cell Therapy Business in the U.S.

Upon opening, it will be staffed by several persons and operate as a branch office of our U.S. subsidiary Sunovion Pharmaceuticals Inc.

Hailed as one of the leading biotechnology clusters in the U.S., San Diego is home to numerous academic institutions and affiliated research laboratories, biotech venture businesses, and biopharmaceutical companies, making it an ideal base for product development, collaborative network building, and information gathering for the Regenerative Medicine/Cell Therapy Business.

Sumitomo Dainippon Pharma is working on six R&D projects for neurological disorders, eye diseases, and other serious medical conditions in the Regenerative Medicine/Cell Therapy fields, in collaboration with academic institutions and biotech venture businesses. With the establishment of this foothold in San Diego, Sumitomo Dainippon Pharma will pursue opportunities for advancing its Regenerative Medicine/Cell Therapy Business in the U.S., as well as in Japan.

Contact:

Tel: +81-6-6203-1407

(C) 2019 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
SUMITOMO CHEMICAL CO LTD 0.00% 504 End-of-day quote.-1.37%
SUMITOMO DAINIPPON PHARMA CO LTD -0.17% 2392 End-of-day quote.-29.54%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SUMITOMO DAINIPPON PHARMA
05/09SUMITOMO DAINIPPON PHARMA : to Open a New Office for its Regenerative Medicine/C..
AQ
05/07SUMITOMO DAINIPPON PHARMA CO LTD : annual earnings release
04/29SUMITOMO DAINIPPON PHARMA : Sumitomo Dainippon Pharma Announces Revision to its ..
AQ
04/12SUMITOMO DAINIPPON PHARMA : Announces Mid-term Business Plan 2022
AQ
04/10Poxel and Sumitomo Dainippon Pharma Announce Positive Top-Line Results for Im..
AQ
04/08SUMITOMO DAINIPPON PHARMA : Five Partners Commence Joint R&D on Renal Regenerati..
AQ
04/03SUMITOMO DAINIPPON PHARMA : Submits an Application of RETHIO for an Additional I..
AQ
03/29SUMITOMO DAINIPPON PHARMA : Kyoto University Innovation Capital Co., Ltd. - Alph..
AQ
03/27SUMITOMO DAINIPPON PHARMA : Receives Approval in Japan for RITHIO for Conditioni..
AQ
03/27SUMITOMO DAINIPPON PHARMA CO LTD : Ex-dividend day for final dividend
FA
More news
Financials (JPY)
Sales 2020 472 B
EBIT 2020 -
Net income 2020 44 123 M
Finance 2020 148 B
Yield 2020 0,86%
P/E ratio 2020 22,47
P/E ratio 2021 20,88
EV / Sales 2020 1,70x
EV / Sales 2021 1,61x
Capitalization 952 B
Chart SUMITOMO DAINIPPON PHARMA CO LTD
Duration : Period :
Sumitomo Dainippon Pharma Co Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SUMITOMO DAINIPPON PHARMA
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 9
Average target price 2 506  JPY
Spread / Average Target 4,8%
EPS Revisions
Managers
NameTitle
Hiroshi Nomura President & Representative Director
Masayo Tada Chairman
Yoshiharu Ikeda General Manager-Research Technology
Nobuyuki Hara Director, Executive Officer & GM-Development
Hitoshi Odagiri Director, Managing Executive Officer & GM-Sales
Sector and Competitors
1st jan.Capitalization (M$)
SUMITOMO DAINIPPON PHARMA CO LTD-29.54%8 643
JOHNSON & JOHNSON7.41%368 017
PFIZER-4.99%230 570
ROCHE HOLDING LTD.9.35%227 259
NOVARTIS13.20%210 489
MERCK AND COMPANY3.02%202 676